Hormonal
Long-acting GLP-1 receptor agonists (liraglutide and semaglutide) improve glycemic control and promote significant weight loss in individuals with type 2 diabetes and obesity by binding to GLP-1 receptors in the pancreas and brain.
GLP-1 agonists like liraglutide and semaglutide are effective treatments for type 2 diabetes and obesity. They work by mimicking a natural hormone to regulate blood sugar and reduce appetite. Liraglutide is approved at 3.0 mg daily for obesity, while semaglutide is being developed for similar uses and oral administration. These drugs target receptors in the pancreas and brain to achieve their effects.
GLP-1Rs in the pancreas and brain have been shown to account for the respective improvements in glycemic control and body weight that are evident with liraglutide and semaglutide.
Why this rating
The paper reviews extensive human and non-human studies, including clinical trials leading to approval.
Source
The Discovery and Development of Liraglutide and Semaglutide
Lotte Bjerre Knudsen et al. · Frontiers in Endocrinology · 2019
DOI 10.3389/fendo.2019.00155
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →